ST
ALXN

Sentinel Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Sentinel Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-36,905
Closed -$3.59M – 91
2018
Q4 		$3.59M Sell
36,905
-9,978
-21% -$1.18M 1.11% 12
2018
Q3 		$6.52M Sell
46,883
-13,264
-22% -$1.66M 1.41% 12
2018
Q2 		$7.47M Sell
60,147
-10,773
-15% -$1.26M 1.67% 10
2018
Q1 		$7.91M Buy
70,920
+36,965
+109% +$4.42M 1.67% 11
2017
Q4 		$4.06M Buy
+33,955
New +$4.14M 0.84% 39

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sentinel Trust's ALXN Position: Q1 2019 in Review

Sentinel Trust sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 36,905 shares — an estimated $3.59M sold.

Sentinel Trust first reported a position in ALXN in Q4 2017 and held it in 5 quarters. The position peaked at $7.91M in Q1 2018. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Sentinel Trust reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Sentinel Trust sold 36,905 Alexion Pharmaceuticals shares in Q1 2019, an estimated $3.59M.
  • Sentinel Trust first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • Sentinel Trust's Alexion Pharmaceuticals position peaked at $7.91M in Q1 2018.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Sentinel Trust's 13F filing for Q1 2019, filed 15 May 2019.